Is Vemurafenib a targeted drug?

Vemurafenib is a targeted drug. Vemurafenib is used to treat melanoma that has spread or cannot be removed by surgery. It is only used when the melanoma cells have the BRAF V600E mutation. Vemurafenib is also used to treat Erdheim-Chester disease (ECD), a type of blood cancer that affects the body's tissues and organs. It is used only if the cancer cells have the BRAF V600 mutation. Vemurafenib is an anti-cancer drug.

Vemurafenibis a competitive kinase inhibitor that is active against mutated BRAF kinases such as V600E. 2 exerts its function by binding to the ATP binding domain of mutated BRAF. Vemurafenib was jointly developed by Roche and Plexxikon and launched in 2011< It was approved by FDA on 17 of August 2018, and was managed by Hoffmann-La Roche. Following the approval, Roche launched an extensive development program in partnership with Genentech.

Vemurafenibis an oral mutantBRAF-serine-threonine kinase inhibitor. Vemurafenibis a small molecule that interacts as a competitive inhibitor of BRAF mutant species. It is particularly effective against the BRAF V600E mutation. Vemurafenibblocks downstream processes to inhibit tumor growth and ultimately trigger apoptosis. Vemurafenibhas no antitumor effect on melanoma cell lines harboring wild-type BRAF mutations. Vemurafenib is an original drug available in Türkiye, with a retail price in pharmacies240 mg, 56 tablets2more than a thousand. If you want to get more high-quality information, you can contact yaode, yaoWe will do our best to help you learn more about high-quality overseas drugs.